Evidence map›Paper›PMID 32822333›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2020

Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade.

Jingjing Chen, Shao Liu, Hui Xu, Wei Wang, Yanyun Xie, Wenbin Tang, Qiongjing Yuan, Li Zheng, Lizhen Lin, Shuangshuang Fu and 1 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Jingjing ChenDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Shao LiuDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Hui XuNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Wei WangDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Yanyun XieDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Wenbin TangDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Qiongjing YuanDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Li ZhengBlood Purification Centre, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Lizhen LinDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Shuangshuang FuDepartment of Nephrology, Hunan Provincial People's Hospital, Changsha, Hunan, China (mainland).
Jinmei ShenDepartment of Anesthesiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Central South University · CNXiangya Hospital Central South University · CNHunan Provincial People's Hospital · CNThird Xiangya Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Recent guidelines recommend that patients with immunoglobulin A nephropathy (IgAN) and proteinuria 0.5-1 g/d and >1 g/d be treated with long-term renin-angiotensin system blockade (RASB). This study investigated whether patients with IgAN and persistent hematuria, but without proteinuria, can benefit from RASB. MATERIAL AND METHODS IgAN patients with persistent hematuria at four centers were recruited from January 2013 to December 2018. Patients were divided into those who did and did not receive long-term RASB. The primary outcome was the appearance of proteinuria, and the secondary outcomes were the decreased percentage of hematuria, rate of decline in estimated glomerular filtration rate (eGFR) and final blood pressure. The effects of RASB on these outcomes were assessed by multivariate Cox regression models and propensity score matching. RESULTS Of the 110 eligible patients, 44 (40.0%) received RASB and 66 (60.0%) did not. Treated patients had higher diastolic pressure. The unadjusted primary outcome, the appearance of proteinuria, was significantly less frequent in individuals who were than who were not treated with RASB. Multivariate Cox regression showed that RASB reduced the risk of the primary outcome and the levels of hematuria. The rate of eGFR decline and final blood pressure did not differ in the two groups. CONCLUSIONS RASB reduced the risk of proteinuria development and increased the remission of hematuria in patients with IgAN who presented with persistent hematuria alone. RASB, however, did not affect blood pressure in patients without hypertension and did not affect the rate of eGFR decline.

Indexed as

AdultAngiotensin-Converting Enzyme InhibitorsBlood PressureFemaleFollow-Up StudiesGlomerular Filtration RateGlomerulonephritis, IGAHematuriaHumansHypertensionMaleMiddle AgedPropensity ScoreProportional Hazards ModelsProteinuriaRenin-Angiotensin SystemAngiotensin-Converting Enzyme Inhibitors

Identifiers

PMID32822333
PMCPMC7456162
OpenAlexW3036442224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.